Patrick Schoeffski
KU Leuven · 24 works · 256 citations · h-index 5
Top works
- 695P A phase I/Ib study evaluating the safety and tolerability of NIZ985 alone and in combination with spartalizumab (anti–PD-1) in patients (pts) with solid tumors or lymphoma
- Combination Chemotherapy With Gemcitabine Plus Oxaliplatin in Patients With Intensively Pretreated or Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group
- Sunitinib-related thyroid dysfunction: A single-center retrospective and prospective evaluation
- The dream and reality of histology agnostic cancer clinical trials
- 452O A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumours
- Cetuximab and irinotecan/5-FU/FA (AIO) as first line treatment in metastatic colorectal cancer (mCRC): Final results and pharmacokinetic data of a phase I/IIa study
- LBA2 DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT)
- 300 Cetuximab/irinotecan/HD-FU/LV in first line therapy of metastatic colorectal cancer (CRC)
- 1621MO Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase I trial update
- 673P A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours
- 452: The Value of Postchemotherapy Surgery in the Management of Patients Harbouring Liver Metatases from Germ Cell Tumors
- Advanced clear-cell renal cell carcinoma (accRCC): Association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome
- 1919P Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: A multicenter EORTC prospective randomized double-blind phase II study (NCT01788982)
- Soft tissue sarcomas express a distinct mRNA immune profile
- Administration of 24-hour intravenous infusions of trabectedin every 3 weeks in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps
- 1514P Anti-tumor effects of the novel KIT mutant inhibitor M4205 in gastrointestinal stromal tumor (GIST) xenograft models
- 110P Chromosomal instability and genomic evolution in gastrointestinal stromal tumours
- Ghrelin is elevated in child C cirrhosis and clinical complications in patients with chronic liver diseases
- 843 Role of surgery in patients with liver metastases from nonseminomatous germ cell tumors
- 2743TiP First-in-human (FIH) phase I/II study of ADCE-D01, a urokinase plasminogen activator receptor-associated protein (uPARAP)-targeted antibody-drug conjugate (ADC) carrying a topoisomerase 1 inhibitor payload, in patients with metastatic and/or unresectable soft tissue sarcoma (STS)